- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 14, 2025
Product Development
As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim
Immuno-oncology asset anchored $625M deal
BioCentury | Jun 28, 2018
Translation in Brief
Conformist nanobodies
How a new synthetic nanobody platform enables conformation-specific binding
BioCentury | Mar 23, 2017
Translation in Brief
High-altitude hypoxia
How studying the effects of altitude sickness led to a new target for treating hypoxia
BioCentury | Nov 19, 2012
Product Development
Clavis counting on PK
After CO-101 blowup, Clavis hopes elacytarabine produces Phase III win in 1Q13
Items per page:
1 - 10 of 29